Organizational and direct support maintenance manual [microform] : generator, smoke, mechanical, pulse jet, M3A4 (1040-01-143-9506).

"October 1985."

Operator's and organizational maintenance manual : pulse form restorer TD-12l9/G, (NSN 5820-01-145-4939).

Includes index.

Direct support, general support, and depot maintenance manual : restorer, pulse form TD-206/G.

"November 1966."

Operator's manual : pulse generator sets AN/UPM-15 and AN/UPM-15A.

"September 1960."

Operator's and organizational maintenance : pulse signal generator SG-1205(V)1/U (NSN 6625-01-137-5369).

"5 December 1983."

Operator's and organizational maintenance manual : multiplexer TD-976/G (NSN 7025-01-048-9678) and pulse form restorer TD-982/G (NSN 7025-01-061-1245).

"October 1979."

Direct support and general support maintenance repair parts and special tools list : multiplexer TD-976/G (NSN 7025-01-048-9678) and pulse form restorer TD-982/G (NSN 7025-01-061-1245).

"14 November 1981."

Exponentially decaying pressure pulse moving with superseismic velocity on the surface of a half space of Von Mises elastoplastic material

Mode of access: Internet.

Early vaccination in New Mexico;

Mode of access: Internet.

Edward Jenner & smallpox vaccination /

Mode of access: Internet.

Pulse Pressure magnifies the effect of COMT Val158Met on 15 Year Episodic Memory Trajectories

We investigated whether a physiological marker of cardiovascular health, pulse pressure (PP), and age magnified the effect of the functional COMT Val158Met (rs4680) polymorphism on 15-years cognitive trajectories [episodic memory (EM), visuospatial ability, and semantic memory] using data from 1585 non-demented adults from the Betula study. A multiple-group latent growth curve model was specified to gauge individual differences in change, and average trends therein. The allelic variants showed negligible differences across the cognitive markers in average trends. The older portion of the sample selectively age-magnified the effects of Val158Met on EM changes, resulting in greater decline in Val compared to homozygote Met carriers. This effect was attenuated by statistical control for PP. Further, PP moderated the effects of COMT on 15-years EM trajectories, resulting in greater decline in Val carriers, even after accounting for the confounding effects of sex, education, cardiovascular diseases (diabetes, stroke, and hypertension), and chronological age, controlled for practice gains. The effect was still present after excluding individuals with a history of cardiovascular diseases. The effects of cognitive change were not moderated by any other covariates. This report underscores the importance of addressing synergistic effects in normal cognitive aging, as the addition thereof may place healthy individuals at greater risk for memory decline.

The Impact of a Group Health Cooperative HPV Vaccination Promotion Program on Initiation of the HPV Vaccine

Thesis (Master's)--University of Washington, 2016-06

Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen

Metastatic melanoma is poorly responsive to treatment, and immunotherapeutic approaches are potentially beneficial. Predictors of clinical response are needed to identify suitable patients. We sought factors associated with melanoma-specific clinical response following intradermal vaccination with autologous melanoma peptide and particulate hepatitis B antigen (HBsAg)-exposed immature monocyte-derived dendritic cells (MDDC). Nineteen patients with metastatic melanoma received a maximum of 8, 2-weekly vaccinations of DC, exposed to HBsAg in addition to autologous melanoma peptides. A further 3 patients received an otherwise identical vaccine that did not include HBsAg. Patients were assessed 1-2 monthly for safety, disease volume, and cellular responses to HBsAg and melanoma peptide. There was no significant toxicity. Of 19 patients receiving HBsAg-exposed DC, 9 primed or boosted a cellular response to HBsAg, and 10 showed no HBsAg response. HBsAg-specific responses were associated with in vitro T cell responses to melanoma peptides and to phytohemagglutinin (PHA). Zero out of 10 non-HBsAg-responding and 4/9 HBsAg-responding patients achieved objective melanoma-specific clinical responses or disease stabilization- 1 complete and 2 partial responses and I case of stable disease (P=0.018). Development of melanoma-specific cellular immunity and T cell responsiveness to mitogen were greater in the group of patients responding to HBsAg. Therefore stimulation of an immune response to nominal particulate antigen was necessary when presented by melanoma peptide-exposed immature DC, to achieve clinical responses in metastatic melanoma. Since general immune competence may be a determinant of treatment response, it should be assessed in future trials on DC immunotherapy.